The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity

Jeff L. Staudinger(GlaxoSmithKline (United States)), Bryan Goodwin(GlaxoSmithKline (United States)), Stacey A. Jones(GlaxoSmithKline (United States)), Diane Hawkins-Brown(GlaxoSmithKline (United States)), Kathleen I. MacKenzie(GlaxoSmithKline (United States)), Anne M. Latour(GlaxoSmithKline (United States)), Yaping Liu(GlaxoSmithKline (United States)), Curtis D. Klaassen(GlaxoSmithKline (United States)), Kathleen K. Brown(GlaxoSmithKline (United States)), John F. Reinhard(GlaxoSmithKline (United States)), Timothy M. Willson(GlaxoSmithKline (United States)), Beverly H. Koller(GlaxoSmithKline (United States)), Steven A. Kliewer(GlaxoSmithKline (United States))
Proceedings of the National Academy of Sciences
March 13, 2001
Cited by 1,353Open Access
Full Text

Abstract

The pregnane X receptor (PXR) is the molecular target for catatoxic steroids such as pregnenolone 16alpha-carbonitrile (PCN), which induce cytochrome P450 3A (CYP3A) expression and protect the body from harmful chemicals. In this study, we demonstrate that PXR is activated by the toxic bile acid lithocholic acid (LCA) and its 3-keto metabolite. Furthermore, we show that PXR regulates the expression of genes involved in the biosynthesis, transport, and metabolism of bile acids including cholesterol 7alpha-hydroxylase (Cyp7a1) and the Na(+)-independent organic anion transporter 2 (Oatp2). Finally, we demonstrate that activation of PXR protects against severe liver damage induced by LCA. Based on these data, we propose that PXR serves as a physiological sensor of LCA, and coordinately regulates gene expression to reduce the concentrations of this toxic bile acid. These findings suggest that PXR agonists may prove useful in the treatment of human cholestatic liver disease.


Related Papers

No related papers found

Powered by citation graph analysis